1FASSHAUER M,PASCHKE R.Regulation of adipocytokines and insulin resistance [ J].Diabetologia,2003,46:1594-1603.
2UNGER R H,ORCI L.Lipotoxic diseases of nonadipose tissues in obesity[ J].Int Obes Relat Metab Disord,2000,24:S28-S32.
3BARBIER O,TORRA J P,DUGUAY Y,et al.Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis [J].Arterioscler Thromb Vasc Biol,2002,22:716-726.
4ROSEN ED,WALKEY C J,PUIGSERVER P,et al.Transcriptional regulation of adipogenesis [J].Genes Dev,2000,14:1293-1307.
5KADOWAKI T,HARA K,YAMAUCHI T,et al.Molecular mechanism of insulin resistance and obesity [ J].Exp Biol Med,2003,228:1111-1117.
6LARSEN T M,TOUBRO S,ASTRUP A.PPAR gamma agonists in the treatment of type Ⅱ diabetes:is y selective ligand for the peroxisome proliferator-activated receptor β/δ [J].Biochem,1996,235:242-247.
7GRIMALDI P A.The roles of PPARs in adipocyte differentiation[J].Prog Lipid Res,2001,40:269-281.
8LIM H,GUPTA R A,MA W G,et al.Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR delta [J].Genes Dev,1999,13:1561-1574.
9TAN N S,MICHALIK L,DESVERGNE B,et al.Peroxisome proliferator-activated receptor beta as a target for wound healing drugs:what is possible [J].Am J Clin Dermatol,2003,4:523-530.
10POIRIER H,NIOT I,MONNOT M C,et al Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine[J].Biochem J,2001,355:481-488.
3Cunxiang Zhao, et al.Arylsulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders[P].US:2005 234 046,2005.
4Malecha,et al. ((5- (2-phenyl)-thiazol-5-ylmethoxy) -indol-1-yl)-acetic acid derivatives and related compounds as modulators of the human PPAR-delta receptor for the treatment of metabolic disorders such as type 2 diaetes[P].WO:2 005 060 958,2005.
5Broo, et al. 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease[P].WO:2 008 108 735,2008.
6Green, et al. Azaindoles useful as inhibitors of rock and other protein kinases[P].WO:2 005 103 050,2065.
